Levetiracetam Eg

Levetiracetam, the active ingredient in Levetiracetam Eg, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients diagnosed with epilepsy, and is marketed throughout the European Union.

GNH USA supplies Levetiracetam Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to control various seizure types. - Partial seizures: reduces the frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes that involve the whole brain. - Myoclonic seizures: diminishes sudden, brief muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Headache: mild to moderate pain in the head region. - Irritability: increased emotional sensitivity or agitation. - Nausea: mild upset stomach or urge to vomit. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Mood changes: including depression, suicidal thoughts, or aggression. - Hematologic abnormalities: rare cases of low blood cell counts. - Hepatic dysfunction: elevated liver enzymes indicating liver stress. - Respiratory depression: uncommon but potentially life‑threatening breathing difficulty. - Anaphylaxis: rare severe allergic response requiring immediate medical attention.

Before initiating therapy, consider the following precautions. - Pregnancy: Category B – use only if potential benefit justifies the potential risk to the fetus. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Psychiatric history: monitor for mood changes, especially in patients with prior depression or anxiety. - Concomitant CNS depressants: may enhance sedation or dizziness. - Driving and machinery: avoid operating heavy equipment until individual response is known. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring clinical monitoring. - Rifampin: can induce metabolism, lowering levetiracetam exposure. - Oral contraceptives: levetiracetam may reduce hormonal contraceptive efficacy; advise alternative birth control. - Alcohol: may exacerbate central nervous system depression and dizziness. - Other antiepileptics: combined use may increase risk of adverse CNS effects.